Lin Honglin-B (02696.HK) announced that its business partner Accord Healthcare S.L.U. The submitted HLX02 license application shall be approved by the PRC. After approval, HLX02 may be listed centrally in all member countries of the League, as well as in Iceland, Liechtenstein and Norway.
HLX02 is a single anti-biological analogue independently developed by the company in accordance with the biological guidelines of China and the League. It is used for the treatment of early HER2 breast cancer, HER2 metastatic breast cancer, and untreated HER2 metastatic gastric cancer or gastric / esophageal junctional adenocarcinoma. (jc/w) ~
Aswick has a new economy.
Web address: www.aastocks.com